Alpha Adrenergic Receptors in Clinical Practice
Present and Future
DOI:
https://doi.org/10.2478/amma-2022-0030Keywords:
alpha adrenergic receptors, molecular target, immunity, noradrenaline, pharmacotherapyAbstract
In this review we discuss the adrenergic pathways for alpha 1 and alpha 2 receptors and the current as well as potential future medication targeting these receptors. Overall, there is ongoing research into a multitude of directions with a promising outlook for alpha 1 and alpha 2 adrenergic receptors. The alpha 1-adrenergic receptor subfamily is currently modulating only a modest number of nervous system functions due the fact, that only a relatively small number of selective commercial products are available. Chronic stress can affect the long-term depression of alpha 1 receptors. Researchers are searching for new molecular targets which might act on these receptors. Presynaptic alpha 2 receptors play an important role in modulating release of several neurotransmitters in the central nervous system. The future of alpha 2 adrenergic receptors in clinical practice looks even more promising and versatile than that of alpha 1 adrenergic receptors. alpha 2 adrenergic receptors show different responses, especially regarding hypertension and heart failure treatment, and current research suggests a genetic component as a cause, which is being explored further.
Downloads
Published
How to Cite
Issue
Section
License
Acta Marisiensis Seria Medica provides immediate open access to its content under the Creative Commons BY 4.0 license.






